Diabetes therapy
Comparative Analysis of Cost-Utility: Chiglitazar Vs. Sitagliptin In Patients With Type 2 Diabetes In China
A new study published in the Journal of Diabetes and its Complications has compared the long-term clinical and economic outcomes of chiglitazar and sitagliptin in patients with type 2 diabetes mellitus (T2DM) in China. The research, conducted by a team of investigators from Shenzhen University, aimed to evaluate the cost-effectiveness